Fig. 4

circCDYL functions as miR-1275 sponge. a qRT-PCR analysis of circCDYL in RNA sample after RIP assay by AGO2 antibody. b Heatmap of miRNA microarray of RNA sample by circCDYL pull-down. c qRT-PCR analysis of miR-1275 in RNA sample by circCDYL pull-down. d qRT-PCR analysis of circCDYL in RNA sample by miR-1275 miRNA pull-down. e Dual luciferase assay of HEK-293 T cells co-transfected with miR-1275 mimic and luciferase reporter containing full length of circCDYL with or without miR-1275 binding site mutant. NC: negative control; WT: wild-type luciferase reporter containing full length of circCDYL. f LC3 dots in mCherry-GFP-LC3-labeled MDA-MB-231 cells. g LC3-II expression in MDA-MB-231 after treatments with miR-1275 mimic or inhibitor, as detected by Western Blot. h Western Blot analysis of LC3-II expression in MDA-231 co-transfected with circCDYL over-expressing plasmid and miR-1275 mimic or co-transfected with circCDYL specific siRNA and miR-1275 inhibitor. i-j. Proliferation level of MCF-7 and MDA-MB-231 detected by cell viability assay (i) and plate colony formation (j) after co-transfection with circCDYL over-expressing plasmid and miR-1275 mimic or co-transfection with circCDYL specific siRNA and miR-1275 inhibitor. All data are shown as the mean ± S.E.M. *P < 0.05, **P < 0.01, ***P < 0.005